Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Xilio Therapeutics (XLO) Accumulated Depreciation & Amortization (2024 - 2025)

Xilio Therapeutics' Accumulated Depreciation & Amortization history spans 1 years, with the latest figure at $7.4 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization changed N/A year-over-year to $7.4 million; the TTM value through Dec 2024 reached $7.4 million, changed N/A, while the annual FY2024 figure was $7.4 million, N/A changed from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $7.4 million at Xilio Therapeutics, up from $6.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $7.4 million in Q4 2024 and bottomed at $6.7 million in Q2 2024.